作者: Pradip P. Kamat
DOI: 10.1007/978-3-030-52555-2_29
关键词:
摘要: Dexmedetomidine (DEX), a central alpha-2-agonist, is being increasingly used in outpatient procedural sedation. Recent concerns about the time-honored hypnotic chloral hydrate’s carcinogenicity, genotoxicity, and more importantly lack of availability US market have led to DEX as viable alternative hydrate sedation both an intravenous (IV) medication intranasal medication.